FindTrial
Sign In

A CLINICAL STUDY TO EVALUATE THE EFFICACY OF ASHTANGA GHRITA IN THE MANAGEMENT OF CHITTODVEGA WITH SPECIAL REFERENCE TO GENERALIZED ANXIETY DISORDER.

A RANDOMIZED OPEN LABELLED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY OF ASHTANGA GHRITA IN THE MANAGEMENT OF CHITTODVEGA WITH SPECIAL REFERENCE TO GENERALIZED ANXIETY DISORDER.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038431
Enrollment
40
Registered
2021-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: ASHTANGA GHRITA: A CLASSICAL AYURVEDA FORMULATION FROM ASHTANGA HRIDAYA WITH INGRIDIENTS VACHA INDHULEKHA BRAHMI MANDOOKAPARNI SHANKAPUSHPI SHATAVARI VRIDHADARUKA AMRITA COW GHEE COW MI

Sponsors

Dr TARA B
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.SUBJECTS SUFFERING FROM GENERALIZED ANXIETY DISORDER BETWEEN AGE GROUP OF 20 TO 60 YEARS IRRESPECTIVE OF GENDER SOCIO ECONOMIC STATUS AND RELIGION. 2.SUBJECTS PRESENTING WITH PROMINENT TENSION WORRY AND FEELINGS OF APPREHENSION ABOUT EVERY-DAY EVENTS AND PROBLEMS FOR A MINIMUM PERIOD OF AT LEAST SIX MONTHS. 3.SUBJECTS FULFILLING CRITERIA BASED ON ICD 10 F41 1 CLASSIFICATION OF MENTAL AND BEHAVIOURAL DISORDERS CODE F41 1 AND THOSE GET SCORE BETWEEN 14-24 IN HAMILTON ANXIETY RATING SCALE MILD 14-17 AND MODERATE 18-24 WILL BE INCLUDED IN THE STUDY.

Exclusion criteria

Exclusion criteria: 1. SUBJECTS SUFFERING FROM PANIC DISORDER F41 PHOBIC ANXIETY DISORDERS F40 OBSESSIVE-COMPULSIVE DISORDER F42 AND HYPOCHONDRIACAL DISORDER F45 2 2. SUBJECTS SUFFERING FROM OTHER PSYCHIATRIC ILLNESSES LIKE MOOD DISORDER, PSYCHOSIS, EPILEPSY. 3. SUBJECTS SUFFERING FROM GENERALIZED ANXIETY DISORDER ASSOCIATED WITH OTHER SERIOUS ILLNESSES THAT WOULD INTERFERE WITH THE TREATMENT. 4. SUBJECTS SUFFERING FROM HYPERTHYROIDISM, ORGANIC MENTAL DISORDER OR PSYCHOACTIVE SUBSTANCE-RELATED DISORDER F1 SUCH AS EXCESS CONSUMPTION OF AMPHETAMINE-LIKE SUBSTANCES, OR WITHDRAWAL FROM BENZODIAZEPINES. 5. SUBJECTS WHO ARE ALREADY TAKING ALLOPATHIC MEDICATION FOR GENERALISED ANXIETY DISORDER. 6. PREGNANT AND LACTATING MOTHERS.

Design outcomes

Primary

MeasureTime frame
REDUCTION IN HAMILTON ANXIETY RATING SCORETimepoint: 45 DAYS—

Secondary

MeasureTime frame
REDUCTION IN SYMPTOMS OF ANXIETY LIKE PROMINENT TENSION, EXCESSIVE WORRY, FEELING OF APPHREHENSION IN DAY TO DAY EVENTS AND PROBLEMSTimepoint: REDUCTION IN SYMPTOMS ON 15TH, 30TH AND 45TH DAY—

Countries

India

Contacts

Public ContactDr TARA B

SRI SRI COLLEGE OF AYURVEDIC SCIENCE AND RESEARCH

lakshmimp1981@gmail.com9448173128

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026